Combination Prophylactic Approach Is Best for Neratinib-Associated Diarrhea in HER2+ Breast Cancer

Brandon Scalea
Published: Tuesday, May 14, 2019
Lauren Nye, MD

Lauren Nye, MD

Loperamide in combination with colestipol should be the preferred prophylactic approach to combatting neratinib (Nerlynx)-associated diarrhea in patients with early-stage HER2-positive breast cancer, according to Lauren Nye, MD.

We don't really know where neratinib fits into this new standard of care, but I don't think we will see it go away. It's important for every trial that we continue looking at ways to control symptoms and side effects, with a greater focus on QoL.

References

  1. Hurvitz SA, Chan A, Iannotti NO, et al. Effects of adding budesonide or colestipol to loperamide prophylaxis on neratinib-associated diarrhea in patients with HER2+ early-stage breast cancer: the CONTROL trial. Presented at: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, TX. Abstract P3-14-01.
  2. Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(3):367-377. doi: 10.1016/S1470-2045(15)00551-3.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x